Fifth Third Bancorp
MDGL icon

Fifth Third Bancorp’s Madrigal Pharmaceuticals MDGL Stock Holding History

Fifth Third Bancorp’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$435K Buy
+832
New +$397K ﹤0.01% 2111
2025
Q2 		– Sell
-1
Closed -$331 – 2611
2025
Q1 		$331 Buy
+1
New +$329 ﹤0.01% 2469

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fifth Third Bancorp's MDGL Position: Q1 2026 in Review

Fifth Third Bancorp opened a new position in Madrigal Pharmaceuticals (MDGL) in Q1 2026: 832 shares worth $435K. The stake represents ﹤0.01% of the portfolio and ranks #2111 among its holdings. This is a return to the name: Fifth Third Bancorp previously reported a position in MDGL as recently as Q1 2025.

Fifth Third Bancorp first reported a position in MDGL in Q1 2025 and has held it in 2 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Fifth Third Bancorp held 832 shares of Madrigal Pharmaceuticals worth $435K as of Q1 2026.
  • Madrigal Pharmaceuticals was a new Fifth Third Bancorp position in Q1 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q1 2026, its #2111 holding.
  • Fifth Third Bancorp first reported a position in Madrigal Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Fifth Third Bancorp's 13F filing for Q1 2026, filed 1 May 2026.